Atopic Dermatitis | Galderma | RD.06.SPR.118161
Pharmaceutical Company/Sponsor:
Galderma
Code:
RD.06.SPR.118161
Title:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Type:
Interventional
Phase:
3
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Drug: Nemolizumab Drug: Placebo
Status:
Enrolling by Invitation
Link for Additional Information:
